Navigation Links
Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
Date:12/6/2011

ANAHEIM, Calif., Dec. 6, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive management will present at the Oppenheimer Healthcare Conference to be held on December 13-14, 2011 in New York.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Tuesday, December 13, 2011 at 2:45 p.m. ET. 

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for 90 days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
2. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
3. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
4. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
9. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
10. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
(Date:9/30/2014)... MAR, Calif. , Sept. 30, 2014 ... for women,s health announces its receipt of a patent ... FemmyCycle menstrual cup has also received FDA clearance in ... Canada, and the CE in Europe. This patent is related ... conjunction with this issuance, the company is releasing FemmyCycle ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Lyme ... funder of Lyme disease research at universities, today announced ... focused on the identification, treatment and cure for Lyme ... had received the most applications in its history—over 20 ... , “While we were pleased to receive so many ...
(Date:9/30/2014)... 30, 2014 UFP Technologies, a ... packaging has recently introduced a custom insulated shipping ... . The new insulated shipper solves the issue ... process. UFP Technologies’ BioShell is a universal storage ... storage, handling and shipping. The insulated shipper keeps ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... and Technology (NIST) and The Johns Hopkins University ... properties of promising new materials with unprecedented sensitivity ... most useful for nanotechnology and industrial applications. , ... (MACS), is a variation on several other spectrometers ...
... N.C., Feb. 25 Cornerstone Therapeutics Inc. (Nasdaq: ... developing and commercializing prescription medications for respiratory disorders, today ... 8:30 AM ET on Thursday, March 26, 2009, to ... ended December 31, 2008. Management will also provide ...
... VINELAND, ON, Feb. 25 /PRNewswire/ - How does a ... to answer that question with its model for the ... horticulture science cluster in Canada, industry will steer the ... Jim Brandle, C.E.O. Vineland Research and Innovation Centre. "And ...
Cached Biology Technology:Nanotechnologists gain powerful new materials probe 2Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call 2Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call 3Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call 4Vineland Enables Industries' Efforts to Build Agri-Science Research Cluster 2
(Date:9/30/2014)... Ill. (September 30, 2014) People who suffer from ... do to control their asthma besides properly taking medications ... new article in the Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), asthma sufferers ... their lifestyle. The woman described in the Annals article ...
(Date:9/29/2014)... Between 1970 and 2010 populations of mammals, birds, ... 52 percent, says the 2014 Living Planet Report ... biodiversity loss occurs disproportionately in low-income countriesand correlates ... , In addition to the precipitous decline in ... warning signs about the overall health of the ...
(Date:9/29/2014)... In order to support the world,s needs ... polymers and more, new and more efficient catalytic ... of researchers, including several from Wayne State University, ... a new grant from the National Science Foundation. ... Design of Multicomponent Materials for Electrocatalytic Cascade Reactions," ...
Breaking Biology News(10 mins):Asthma symptoms kicking up? Check your exposure to air pollution 2Half of global wildlife lost, says new WWF report 2Wayne State research aims to develop new, more efficient catalytic materials 2
... Investigators have discovered that some type of protective system ... immune system is deficient. This discovery indicates a hidden ... diseases of the immune system such as AIDS. The ... and Baltimore, and is reported in the early online ...
... Medical Center have uncovered part of the genetic mechanism that ... , A team led by SFVAMC vascular surgeon Rajabrata Sarkar, ... is essential for the growth of new arteries when the ... identified and described, for the first time, the specific DNA ...
... in Brazil 40 years ago, Marc A. Meyers marveled at ... on the forest floor. Now a materials scientist and professor ... Engineering, Meyers said makers of airplanes and automobiles may benefit ... conducted in his lab. , "Our computer modeling done shows ...
Cached Biology News:Infant transplant patients resist infections that kill adult AIDS patients 2Infant transplant patients resist infections that kill adult AIDS patients 3Genetic key to growth of new arteries is identified 2Genetic key to growth of new arteries is identified 3Engineers discover why toucan beaks are models of lightweight strength 2
... The FailSafe™ PCR System is the ... the first time and every time. It ... regardless of the source or the property ... EPICENTRE's FailSafe™ PCR Enzyme Mix, a unique ...
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
... the denaturation and hybridization steps in slide-based ... clinical and research personnel. The low cost ... types, is easy to use, and reduces ... ensuring overall precision and accuracy in all ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
Biology Products: